An Open-Label, Single-Arm Study Of Autologous Anti-Her2 Chimeric Antigen Receptor Monocytes (Ct-0525), In Participants With Her2 Over Expressing Solid Tumors
Posted Date: Apr 26, 2024
- Investigator: Davendra Sohal
- Specialties:
- Type of Study: Drug
This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies.
Criteria:
Null
Keywords:
Solid Tumors
For More Information:
Kayla Webb
NULL
cancer@uchealth.com